Phenacetin acts as a weak genotoxic compound preferentially in the kidney of DNA repair deficient Xpa mice.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Speksnijder, Ewoud N
Alphen, Niels van
Heisterkamp, Siem H
Benthem, Jan van
Kreijl, Coen F van
Beems, Rudolf B
Steeg, Harrym van
MetadataShow full item record
TitlePhenacetin acts as a weak genotoxic compound preferentially in the kidney of DNA repair deficient Xpa mice.
PubliekssamenvattingChronic use of phenacetin-containing analgesics has been associated with the development of renal cancer. To establish genotoxicity as a possible cause for the carcinogenic effect of phenacetin, we exposed wild type and DNA repair deficient Xpa-/- and Xpa-/-/Trp53+/- mice (further referred as Xpa and Xpa/p53 mice, respectively), carrying a reporter lacZ gene, to 0.75% (w/w) phenacetin mixed in feed. Xpa mice completely lack the nucleotide excision repair pathway, and as such they are sensitive to some classes of genotoxic compounds. Phenacetin exposure induced a significant increase of lacZ mutations in the kidney of both Xpa and Xpa/p53 mice. A minor response was found in liver, whereas no lacZ mutation induction was observed in the spleen of these animals. Interestingly, the observed phenacetin-induced mutant frequencies were higher in male than those found in female mice. This gender difference is probably due to a difference in metabolic rate. Phenacetin-induced mutations mainly consisted of point mutations rather than deletions. The mutational spectra in the kidney of treated WT and Xpa mice were quite similar. Taken together, these results demonstrate that the human carcinogen phenacetin acts as a weak genotoxic agent in an in vivo mouse model system.
- Effect of heterozygous loss of p53 on benzo[a]pyrene-induced mutations and tumors in DNA repair-deficient XPA mice.
- Authors: van Oostrom CT, Boeve M, van Den Berg J, de Vries A, Dollé ME, Beems RB, van Kreijl CF, Vijg J, van Steeg H
- Issue date: 1999
- p53 heterozygosity results in an increased 2-acetylaminofluorene-induced urinary bladder but not liver tumor response in DNA repair-deficient Xpa mice.
- Authors: Hoogervorst EM, van Oostrom CT, Beems RB, van Benthem J, Gielis S, Vermeulen JP, Wester PW, Vos JG, de Vries A, van Steeg H
- Issue date: 2004 Aug 1
- Induction of DNA adducts and mutations in spleen, liver and lung of XPA-deficient/lacZ transgenic mice after oral treatment with benzo[a]pyrene: correlation with tumour development.
- Authors: de Vries A, Dollé ME, Broekhof JL, Muller JJ, Kroese ED, van Kreijl CF, Capel PJ, Vijg J, van Steeg H
- Issue date: 1997 Dec
- Finding transcriptomics biomarkers for in vivo identification of (non-)genotoxic carcinogens using wild-type and Xpa/p53 mutant mouse models.
- Authors: Jonker MJ, Bruning O, van Iterson M, Schaap MM, van der Hoeven TV, Vrieling H, Beems RB, de Vries A, van Steeg H, Breit TM, Luijten M
- Issue date: 2009 Oct
- Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.
- Authors: Lina BA, Woutersen RA, Bruijntjes JP, van Benthem J, van den Berg JA, Monbaliu J, Thoolen BJ, Beems RB, van Kreijl CF
- Issue date: 2004 Mar-Apr